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Reactive oxygen species mediate high glucose–induced plas-
minogen activator inhibitor-1 up-regulation in mesangial cells
and in diabetic kidney.
Background. Plasminogen activator inhibitor-1 (PAI-1) plays
an important role in remodeling of extracellular matrix (ECM)
in the glomeruli. PAI-1 is up-regulated by high glucose and is
overexpressed in diabetic kidney. Since reactive oxygen species
(ROS) mediate ECM accumulation in diabetic glomeruli and
was recently found to mediate transforming growth factor-b1
(TGF-b1)-induced PAI-1 up-regulation in glomerular mesan-
gial cells, we examined the role of ROS in high glucose–induced
PAI-1 expression in cultured glomerular mesangial cells and in
streptozotocin-induced diabetic rat glomeruli.
Methods. Growth arrested and synchronized primary rat
mesangial cells were treated with different concentrations of
glucose in the presence or absence of N-acetylcysteine (NAC) or
trolox, or after cellular reduced form of glutathione (GSH) de-
pleted with DL-buthionine-(S,R)-sulfoximine (BSO). Taurine
was administered to diabetic rats from 2 days to 4 weeks after
streptozotocin injection. Urinary protein excretion, glomeru-
lar volume, and fractional mesangial area were measured
as markers of renal injury and lipid peroxide (LPO) as an
oxidative stress marker. PAI-1 mRNA expression was mea-
sured by Northern blot analysis in mesangial cells and re-
verse transcription-polymerase chain reaction (RT-PCR) in
glomeruli, PAI-1 protein by Western blot analysis and enzyme-
linked immunosorbent assay (ELISA), and plasmin activity by
fluorometry.
Results. High glucose significantly increased PAI-1 mRNA
and protein expression and decreased plasmin activity in mesan-
gial cells. Equimolar concentrations of L-glucose or mannitol
did not affect PAI-1 expression. BSO pretreatment significantly
increased basal PAI-1 expression and amplified the response to
high glucose. NAC effectively inhibited high glucose–induced,
but not basal, PAI-1 expression. Reduced plasmin activity in
mesangial cells by high glucose was rescued by antioxidants.
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Anti-TGF-b antibody inhibited both high glucose– and H2O2-
induced PAI-1 up-regulation. Taurine significantly reduced
plasma LPO, glomerular PAI-1 expression, glomerular volume,
fractional mesangial area, and proteinuria in streptozotocin-
induced diabetic rats.
Conclusion. These results demonstrate that ROS mediate
high glucose–induced up-regulation of PAI-1 expression in cul-
tured mesangial cells and in diabetic glomeruli. Since both high
glucose and TGF-b1 induce cellular ROS and ROS mediate
both high glucose– and TGF-b1–induced PAI-1, ROS appear
to amplify TGF-b1 signaling in high glucose–induced PAI-1
up-regulation. Antioxidants can prevent accumulation of ECM
protein in diabetic glomeruli partly by abrogating up-regulation
of PAI-1 and suppression of plasmin activity.
Diabetic nephropathy is characterized by glomeru-
losclerosis and tubulointerstitial fibrosis as a result of
overproduction and/or decreased degradation of ex-
tracellular matrix (ECM) in the kidney. This process
had been considered irreversible until Fioretto et al [1]
showed the regression of diabetic nephropathy by normo-
glycemia of more than 10 years after pancreas transplan-
tation in type 1 diabetes. This suggests that the glomerular
and tubulointerstitial fibrosis is reversible and that degra-
dation of ECM plays an important role in ECM remod-
eling in diabetic kidney.
Two main enzyme systems, plasminogen activator
(PA)/plasmin/PA inhibitor (PAI) system and matrix met-
alloproteinase (MMP)/tissue inhibitor of metallopro-
teinase (TIMP) system, are involved in ECM degradation
[2–6]. Plasmin, a key ECM degrading enzyme, is gen-
erated from plasminogen by tissue type and urokinase
type PA (tPA and uPA). MMPs, another ECM degrading
proteases, require plasmin for the activation from their
latent forms. Plasminogen activator inhibitor-1 (PAI-1)
interferes with the generation of plasmin and activation
of MMP by blocking PA. PAI-1 may thus play a critical
role in ECM remodeling in the kidney [7, 8].
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PAI-1 is a 50 kD single chain glycoprotein originat-
ing from various cells, including glomerular mesangial
cells, vascular endothelial cells, fibroblasts, hepatocytes,
adipocytes, and inflammatory cells [9]. PAI-1 is secreted
into the plasma immediately after synthesis and is acti-
vated by binding vitronectin. PAI-1 exists mostly (about
80%) as an active form and the remainder in latent
form bound to plasma proteins or complex with tPA.
While normal human kidneys do not express PAI-1 [7],
PAI-1 is overexpressed in pathologic conditions associ-
ated with renal fibrosis, including thrombotic microan-
giopathy [10], hypertensive nephrosclerosis [11], renal
vasculitis [12], proliferative glomerulonephritis [13–15],
aging kidney [16], obstructive uropathy [17], and dia-
betic nephropathy [11, 18–20]. PAI-1 expression is up-
regulated by high glucose in glomerular mesangial cells
[21, 22]. However, the signals and pathways involved in
high glucose–induced PAI-1 up-regulation have not been
clearly elucidated.
Cellular reactive oxygen species (ROS) are increased
in diabetes and contribute to pathogenesis of chronic
vascular complications including nephropathy [23–31].
Hyperglycemia-induced mitochondrial superoxide over-
production was shown to induce PAI-1 expression in
the vascular endothelial cells [25]. We recently demon-
strated that TGF-b1–induced PAI-1 up-regulation in
mesangial cells is mediated by ROS [32]. ROS have also
been shown to mediate cyclic strain-induced PAI-1 re-
lease from endothelial cells [33] and radiation-induced
PAI-1 up-regulation in renal tubular epithelial cells [34].
The present study, therefore, examined the role of ROS
in high glucose–induced PAI-1 expression by utilizing
cultured glomerular mesangial cells and streptozotocin-
induced diabetic rat glomeruli.
METHODS
All chemicals and tissue culture plates were obtained
from Sigma-Aldrich Company (St. Louis, MO, USA) and
Becton Dickinson Labware (Lincoln Park, NJ, USA), re-
spectively, unless otherwise stated.
Mesangial cell culture
Primary rat mesangial cells were isolated from kid-
neys of 100 to 150 g male Sprague-Dawley rats by a
conventional sieving method and characterized as de-
scribed previously [29]. Cells (between the eighth and
twelvth passages) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco BRL, Gaithersberg,
MD, USA) containing 20% fetal bovine serum (FBS)
(Gibco BRL), 100 U/mL penicillin, 100 lg/mL strepto-
mycin, 44 mmol/L NaHCO3, and 14 mmol/L N-hydroxy-
ethylpiperazine-N′-2-ethane sulfonic acid (Hepes).
Cells were cultured in 100 mm culture dish for North-
ern blot analysis, in 6-well plates for Western blot analysis
and plasmin activity. Near confluent mesangial cells were
incubated with serum-free media for 24 hours to arrest
and synchronize the cell growth. After this time period,
the media were changed to fresh serum-free and phenol
red-free DMEM containing different concentrations of
D-glucose, 25 mmol/L L-glucose, or 25 mmol/L mannitol
for up to 48 hours. In some experiments, cells were pre-
treated with 1 mmol/L DL-buthionine-(S,R)-sulfoximine
(BSO) for 24 hours to deplete intracellular glutathione or
with antioxidants [5 mmol/L N-acetylcysteine (NAC) or
500 lmol/L trolox (Aldrich Chemical Co., Milwaukee,
WI, USA)], 1 lg/mL anti-transfroming growth factor-b 1
(TGF-b1) antibody (Genzyme Diagnostics, Cambridge,
MA, USA), or control IgG for 1 hour before the addition
of glucose. BSO pretreatment decreased intracellular re-
duced form of glutathione (GSH) from 10.96 ± 0.43 to
4.82 ± 0.49 nmol/mg of cell protein in mesangial cells
under the present experimental condition. The effective
concentrations of antioxidants were decided based on our
published data [24, 29, 32]. Cells were processed for mea-
surement of PAI-1 mRNA and media for protein expres-
sion and plasmin activity at the end of incubation period
as described below.
Induction of experimental diabetes mellitus
Male Sprague-Dawley rats weighing 200 to 250 g were
obtained from Biogenomics, Seoul, Korea. The animals
were housed two to three per cage in an animal room
controlled at 23 ± 2◦C and 55 ± 5% room humidity, un-
der a 12-hour light and 12-hour dark cycle. All rats were
maintained on standard rat chow (Samyang Rat Chow,
Seoul, Korea) and tap water ad libitum.
Diabetes was induced by administration of 50 mg/kg
of streptozotocin dissolved in pH 4.5 citrate buffer into
the tail vein, as described previously [24]. Control rats
received the same volume of citrate buffer (1 mL/kg). In-
duction of diabetes was confirmed by determining plasma
glucose 2 days after streptozotocin injection. Rats with
plasma glucose level above 300 mg/dL were used as di-
abetic rats. A group of diabetic rats was treated with
taurine (Yakuri Pure Chemical Co., Tokyo, Japan) 1%
solution in drinking water starting 2 days after streptozo-
tocin. Diabetic rats receiving no taurine served as diabetic
control. All diabetic rats survived without insulin treat-
ment in the present study. We did not administer insulin
to avoid nonmetabolic effects of insulin.
At the end of given experimental periods, 1 and 4 weeks
after streptozotocin injection, blood samples were drawn
from each animal for measurement of plasma glucose,
and lipid peroxide (LPO). Urine samples were collected
over a 24-hour period for 2 consecutive days for pro-
tein and LPO level. After sacrifice, both kidneys were
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removed and weighed. Glomeruli from the left kidney
were isolated by conventional graded sieving method to
assess PAI-1 mRNA (1 week after streptozotocin) and
PAI-1 protein (4 weeks after streptozotocin). The right
kidney was fixed with 10% formalin for assessment of
glomerular morphology.
Measurement of LPO in plasma and urine
A modification of the thiobarbituric acid method of
Ohkawa, Ohishi, and Yagi [35] was used to measure LPO,
as previously described [24]. In brief, after mixing di-
luted plasma or urine specimen with 8% sodium dode-
cyl sulfate (SDS), reaction solution composed of 0.8%
2-thiobarbituric acid and 20% acetic acid was added and
incubated at a 95◦C water bath for 60 minutes. After stop-
ping the reaction by cooling with tap water, the mixture
was centrifuged at 15,000g for 5 minutes to precipitate in-
terfering particulate materials. The amount of malondi-
aldehyde formed was determined by spectrophotometry
(Beckman Coulter DU 530; Beckman Coulter, Fuller-
ton, CA, USA) at wavelength 535 nm and calculated us-
ing a tetraethoxypropane standard curve.
Measurement of urinary protein
Urine samples were centrifuged at 3000g for 10 min-
utes, and urinary protein in the supernatants was deter-
mined by Bradford method [36]. All samples were as-
sayed in triplicate and the mean value from a given rat
was calculated.
Measurement of glomerular volume and fractional
mesangial area
In each rat, at the end of 4 weeks after streptozo-
tocin, quantitative morphometric analysis of different
glomeruli were performed as described previously [30]
by a blinded observer. A 5 lm thick section was stained
with periodic acid-Schiff (PAS) reagent. On this section,
30 different superficial glomeruli were randomly sampled
for morphometric analysis. The microscopic slide was
scanned clockwise along the superficial cortex and one
glomerulus out of three was analyzed. For every inves-
tigated glomerulus, total glomerular area and glomeru-
lar tuft area were determined by tracing the outline of
the Bowman’s capsule and the tuft, respectively, using
Image-Pro Plus 4.5 software (Media Cybernetics, Silver
Spring, MD, USA). Fractional mesangial area was calcu-
lated as the percentage of area positive for PAS occupying
glomerular tuft area. Glomerular volume was determined
by the following formula.
Glomerular volume
= B/k(cross-sectional area of a glomerulus)3/2
Where B (=1.38) is the shape coefficient for spheres, and
k (=1.1) is a size distribution coefficient.
Northern blot analysis for PAI-1 mRNA expression by
cultured mesangial cells
Total RNA from mesangial cells was isolated by the
single step method using TRIzol Reagent (Invitrogen
Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Twenty micrograms of total
RNA was denatured and separated by electrophoresis
through a 1.2% agarose gel with 2.2 mol/L formalde-
hyde, transferred onto nylon membranes (Amersham
Pharmacia Biotech, Buckinghamshire, UK) using a cap-
illary transfer, and covalently cross-linked to the mem-
brane with ultraviolet light using a gene-linker (Bio-Rad,
Richmond, CA, USA). The membranes were hybridized
with 32P-labeled cDNA probe for PAI-1 overnight at 65◦C
in buffer containing 50% formaldehyde and then rehy-
bridized with a probe for glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) as an internal control to assess
RNA quantity and integrity. Quantification of mRNA sig-
nals was performed by densitometry and normalized with
GAPDH mRNA signals.
Reverse transcriptase-polymerase chain reaction
(RT-PCR) for glomerular PAI-1 mRNA expression
Total RNA was extracted from lysate of isolated
glomeruli using TRIzol reagent as in mesangial cells. One
microgram of RNA/20 lL reaction volume was com-
bined with random hexamer primers (2.5 lmol/L) and
reaction components for 30 minutes at 42◦C and then
heated to 95◦C for 4 minutes to inactivate the enzyme
and to denature RNA-cDNA hybrids. cDNA amplifica-
tion was performed at a final concentration of 1× PCR
buffer, 1.5 mmol/L MgCl2, 200 lmol/L deoxynucleoside
triphosphate (dNTP), 10 pmol/L of PAI-1 primers or
GAPDH primers, and 1.25 U of AmpliTaq DNA poly-
merase (Promega Corp., Madison, WI, USA) in a to-
tal volume of 40 lL. cDNA probes for rat PAI-1 and
GAPDH were constructed based on the previously pub-
lished sequences using the PCR: GAPDH sense 5′-ATG
GTC TAC ATG TTC CAG TA-3′, antisense 5′-TCA
GAT CCA CAA CGG ATA CA-3′; and PAI-1 sense
5′-ATG GAA CAA GAA TGA GAT CA-3′, antisense
5′-TCA GTC TCC AGA GAG AAC TT-3′. The amplifi-
cation profile involved denaturation at 95◦C for 1 minute,
primer annealing at 61◦C for PAI-1 or at 55◦C for
GAPDH for 1 minute, and extension at 72◦C for 1 minute.
Final PCR products were electrophoresed in 1% agarose
gel containing 0.2 lg/mL ethidium bromide. The ex-
pected size of the amplified fragments was 471 and 590
bp for PAI-1 and GAPDH, respectively. Quantification
of mRNA bands was performed by densitometry using
TINA 2.0 Image program and normalized with GAPDH
mRNA signals.
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Immunoblot analysis of PAI-1 protein
Immunoblot analysis was performed to determine PAI-
1 protein in the cell culture media and lysate of isolated
rat glomeruli. After measuring the concentration of cellu-
lar protein using Bio-Rad assay, aliquots of media corre-
sponding to the same cellular protein were mixed with
sample buffer containing SDS and b-mercaptoethanol
and heated at 95◦C for 15 minutes. Samples were applied
to 10% polyacrylamide gel and electrophoresed. After
electrophoresis, the proteins were transferred onto nitro-
cellulose membranes using a transblot chamber with Tris
buffer. Western blots were incubated with rabbit antirat
PAI-1 (1:1000) (American Diagnostica, Greenwich, CT,
USA) overnight at 4◦C, washed with phosphate-buffered
saline (PBS)-Tween 20 for 1 hour, and incubated with
peroxidase-conjugated secondary antibody, rabbit anti-
IgG for 2 hours at room temperature. After washing,
the membranes were incubated with enhanced chemi-
luminescence (ECL) detection reagent (Amersham Life
Science) according to the manufacturer’s instructions.
Positive immunoreactive bands were quantitated densit-
ometrically and normalized by b-actin, and were com-
pared with those of control.
Enzyme-linked immunosorbent assay (ELISA)
of PAI-1 protein
To quantify the level of PAI-1 protein secreted into
the media under different experimental conditions, PAI-1
was measured in mesangial cell culture supernatant using
a commercial solid phase quantitative sandwich ELISA
kit for PAI-1 (American Diagnostica, Inc., Greenwich,
CT, USA) according to the manufacturer’s instructions
[32]. The assay reacts with latent, active, and inactive PAI-
1 as well as tPA/PAI-1 complexes. ELISA kits for PAI-1
are specific for rat PAI-1 according to the manufacturer’s
instructions.
Measurement of plasmin activity
Plasmin activity in the culture media was determined as
previously described [32] using a synthetic fluorometric
plasmin substrate methoxysuccinyl-L-Ala-L-Phe-L-Lys-
7-amido-4-methyl-coumarin. Twenty-five microliter of
fivefold concentrated media were mixed with 31.2 lL
of dH2O and 112.5 lL of 0.2 mol/L Tris-HCl, pH 7.4,
containing 0.2 mol/L NaCl. Each reaction was started by
adding 56.3 lL of the substrate in water (final concentra-
tion 5.0 lmol/L). Immediately after the addition of sub-
strate, each tube was mixed well, transferred to a 37◦C
water bath, and incubated for 40 minutes. After the incu-
bation period, each reaction was stopped by the addition
of 25 lL of soya bean trypsin inhibitor. The fluorescence
of each sample was measured in a fluorometer (Wallac
Victor3 1420 Multilabel Counter) (Turku, Finland) at an
emission wave length at 450 nm at an excitation wave
length of 360 nm and calculated using a plasmin standard
curve.
Statistical analysis
All results are expressed as means ± standard error
(SE). Analysis of variance (ANOVA) was used to assess
the differences between multiple groups. If the F statis-
tics was significant, the mean values obtained from each
group were then compared by Fisher’s least significant
difference method. P value < 0.05 was used as the crite-
rion for a statistically significant difference.
RESULTS
High glucose up-regulates PAI-1 mRNA and protein
expression and suppresses plasmin activity in
mesangial cells
Thiry millimoles per liter glucose up-regulated PAI-1
mRNA expression by 1.3-fold that of control at 6 hours
and 1.6-fold at 12 hours. The up-regulation remained sig-
nificant up to 24 hours (Fig. 1A). High glucose also in-
creased PAI-1 protein secretion by mesangial cells by
1.5-fold that of control (Fig. 2) at 48 hours and suppressed
plasmin activity to 70% of control (Fig. 3) at 48 hours.
Basal PAI-1 secretion was 15.6 ± 7.7 ng/lg of cellular pro-
tein as measured by ELISA in mesangial cells maintained
in serum-free DMEM for 48 hours and basal plasmin
activity 2.8 ± 0.8 mU/lg cellular protein. High glucose
increased PAI-1 protein to 24.9 ± 12.7 ng/lg of cellular
protein and decreased plasmin activity to 2.1 ± 0.5 mU/lg
cellular protein. Addition of 25 mmol/L concentration of
L-glucose or mannitol to media containing 5.6 mmol/L
D-glucose did not affect PAI-1 expression (Fig. 2A).
Effects of depletion of cellular reduced GSH on PAI-1
expression in mesangial cells
Depletion of intracellular GSH in mesangial cells by
pretreatment with BSO significantly up-regulated high
glucose–induced as well as basal PAI-1 mRNA expression
at 12 hours (Fig. 1B). Qualitatively similar effect of BSO
on both basal and high glucose–induced PAI-1 protein
secretion at 48 hours was observed (Fig. 2B).
Effects of antioxidants on high glucose–induced PAI-1
expression and plasmin activity in mesangial cells
NAC at 5 mmol/L effectively inhibited high glucose–
induced PAI-1 mRNA (Fig. 1C) and protein (Fig. 2C)
expression without significant effect on basal PAI-1
expression. Trolox at 500 mmol/L also inhibited high
glucose–induced, but not basal, PAI-1 protein secretion
(Fig. 2C). Catalase at 500 U/mL also effectively inhib-
ited high glucose–induced, but not basal, PAI-1 protein
secretion (data not shown). NAC and trolox rescued high
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Fig. 1. Effect of high glucose (A), DL-buthionine-(S,R)-sulfoximine (BSO) (B), and N-acetylcysteine NAC (C) on plasminogen activator inhibitor-
1 (PAI-1) mRNA expression in mesangial cells. Synchronized quiescent mesangial cells were stimulated with 5.6 mmol/L (control) or 30 mmol/L
glucose (high glucose) up to 48 hours. BSO was added 24 hours before the addition of high glucose and NAC 1 hour before. The upper panel shows
a representative Northern blot analysis and the lower panel represents fold increases relative to control in mean ± SE of four to six experiments.
∗P < 0.05 compared to control glucose; +P < 0.05 compared to high glucose. Glc is glucose; GADPH is glyceraldehyde-3-phosphate dehydrogenase.
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Fig. 2. Effect of L-glucose and mannitol on plasminogen activator protein-1 (PAI-1) protein secretion (A) and effect of DL-buthionine-(S,R)-
sulfoximine (BSO) (B) and antioxidants (C) on high glucose–induced PAI-1 protein secretion by mesangial cells. Synchronized quiescent mesangial
cells were stimulated with 30 mmol/L of D-glucose, 25 mmol/L of L-glucose or mannitol added to media containing 5.6 mmol/L D-glucose (A). In
separate experiments, synchronized quiescent mesangial cells were stimulated with control or high glucose in the presence and absence of BSO
(B) or antioxidants (C) for 48 hours. The upper panel shows a representative Western blot analysis and the lower panel represents fold increases
relative to control in mean ± SE from six experiments. ∗P < 0.05 compared to control glucose; +P < 0.05 compared to high glucose. Glc is glucose;
NAC is N-acetylcysteine.
glucose–induced decrease in plasmin activity to control
level (Fig. 3).
Role of TGF-b1 in high glucose–induced PAI-1
expression in mesangial cells
Since TGF-b1 increases PAI-1 expression through
ROS [32] and ROS up-regulate TGF-b1 expression in
mesangial cells [37], we determined the role of TGF-b1
in high glucose–induced PAI-1 up-regulation using anti-
TGF-b antibody. High glucose–induced PAI-1 protein se-
cretion was effectively inhibited by anti-TGF-b antibody
but not by IgG (Fig. 4A). Anti-TGF-b1 antibody did not
affect basal PAI-1 secretion (data not shown). H2O2 in-
creased PAI-1 secretion as in our previous study [32] and
anti-TGF-b antibody effectively inhibited H2O2-induced
PAI-1 up-regulation (Fig. 4B).
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Fig. 3. Effect of antioxidants on high glucose–induced plasmin activity
in mesangial cells. Synchronized quiescent mesangial cells were stimu-
lated with control or high glucose in the presence and absence of an-
tioxidants. Basal plasmin activity was 2.72 ± 0.87 mU/mg cell protein.
Data are presented as fold increases relative to control in mean ± SE
from four experiments. ∗P < 0.05 compared to control glucose; +P <
0.05 compared to high glucose. Glc is glucose; NAC is N-acetylcysteine.
PAI-1 expression in diabetic rat glomeruli and effect
of an antioxidant taurine
Glomerular PAI-1 mRNA expression was significantly
up-regulated in diabetic rats compared to control rats
at 1 week after streptozotocin. Taurine effectively inhib-
ited glomerular PAI-1 mRNA expression in diabetic rats
(Fig. 5A). Glomerular PAI-1 protein expression also in-
creased in diabetic rats at 4 weeks, but the difference did
not reach statistical significance. Taurine, however, sig-
nificantly reduced glomerular PAI-1 secretion (Fig. 5B).
Evidence of oxidative stress in diabetic rats and effect
of taurine
Plasma LPO level increased significantly in diabetic
rats compared to control and was effectively inhibited by
taurine at both 1 and 4 weeks (Fig. 6A). Urinary LPO
level was also significantly higher in diabetic than in con-
trol rats at both 1 and 4 weeks (Fig. 6B). Taurine reduced
urinary LPO excretion but the difference did not reach
statistical significance.
Renal injury in diabetic rats and effect of taurine
Diabetic rats failed to gain body weight compared to
control rats. Taurine did not affect plasma glucose levels
or weight gain (Table 1). The mean kidney weight of di-
abetic rats was significantly higher than control rats at 1
week and kidney/body weight ratio in diabetic rats signif-
icantly higher than that of control at both 1 and 4 weeks
(Table 1). Glomerular volume (Fig. 7A) and fractional
mesangial area (Fig. 7B) also significantly increased in
diabetic rats compared to those of control. Urinary pro-
tein excretion was significantly increased at 1week after
streptozotocin (data not shown) and increased further at
4 weeks (Fig. 7C). Taurine did not affect kidney weight
(Table 1) but significantly reduced glomerular volume
(Fig. 7A), fractional mesangial area (Fig. 7B), and pro-
tein excretion (Fig. 7C) in diabetic rats at 4 weeks after
streptozotocin.
DISCUSSION
We [24, 29, 31] and others [27, 28] have shown that ROS
play a major role in hyperglycemia-induced ECM up-
regulation in both cultured mesangial cells and in diabetic
glomeruli. We previously reported that high glucose, but
not media hyperosmolality, increased dichlorofluorescin
(DCF)-sensitive cellular ROS [29] and that H2O2 contin-
uously generated by glucose oxidase up-regulated PAI-1
mRNA and protein expression and suppressed plasmin
activity in mesangial cells [32]. PAI-1 is overexpressed
in diabetic kidneys [11, 18–20] and mesangial cell PAI-
1 expression is up-regulated by high glucose [21, 22].
The present study confirms that high glucose, but not
hyperosmolality, up-regulates PAI-1 expression in cul-
tured mesangial cells and in streptozotocin-induced di-
abetic rat glomeruli and suppresses plasmin activity in
mesangial cells. The observation that antioxidants effec-
tively inhibit high glucose–induced up-regulation of PAI-
1 and suppression of plasmin activity provides evidence
that hyperglycemia-induced ROS may also play a role
in ECM degradation, independent of their well recog-
nized role in ECM synthesis and secretion, and suggests
the importance of ROS in ECM remodeling in diabetic
glomeruli.
ROS have been shown to mediate PAI-1 expression
in different cells. Hyperglycemia- [25] and cyclic strain
[33]-induced PAI-1 expression in endothelial cells and
radiation-induced PAI-1 expression in rat renal tubular
epithelial cells [34] are mediated by ROS. Uchida et al
[38] recently reported that high glucose, advanced gly-
cation end products (AGEs), and 4-hydroxy-2-nonrenal
up-regulate PAI-1 mRNA and protein expression in rat
white adipocytes through ROS. In mesangial cells, we
[32] showed that ROS mediate TGF-b1–induced PAI-1
mRNA and protein expression. Streptozotocin-induced
diabetic rats with superimposed deoxycorticosterone ac-
etate (DOCA)/salt hypertension had upregulation of
PAI-1, vascular endothelial growth factor (VEGF), and
TGF-b1 in the kidney and this was effectively inhibited
by treatment with a cyclooxygenase-2 inhibitor [11]. On
the other hand, Tada et al [39] reported decreased PAI-1
expression in mesangial cells cultured under high glu-
cose. PAI-1 release was not altered in human peritoneal
mesothelial cells cultured under high glucose [40]. Al-
though the reasons for this discrepancy are not clear, reg-
ulation of PAI-1 expression may vary in different cells and
under different experimental conditions.
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after streptozotocin injection was measured
by reverse transcription-polymerase chain re-
action (RT-PCR) and PAI-1 protein from 4
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We observed in the present study that depletion of
cellular GSH by BSO increased basal as well as high
glucose–induced PAI-1 secretion. We also observed in
a previous study that dehydroisoandrosterone-3-acetate
(DHEA), an uncompetitive inhibitor of G6PD and a
rate-limiting enzyme for regeneration of principal in-
tracellular reductant nicotinamide adenine dinucleotide
phosphate (NADPH), increased basal as well as high
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Table 1. Characteristics of study animals
Kidney weight/body Plasma glucose
Group Number Body weight g Kidney weight g weight mg/g mg/dL
1 week CR 6 321.0 ± 6.1 1.5 ± 0.1 9.3 ± 0.7 167.2 ± 6.5
DR 7 277.9 ± 11.2a 1.8 ± 0.1a 13.4 ± 0.6a 648.0 ± 55.2a
DR + T 7 273.1 ± 11.4a 1.7 ± 0.1a 12.7 ± 0.8a 755.0 ± 49.1a
4 week CR 6 466.7 ± 17.2 1.8 ± 0.1 7.6 ± 0.4 185.2 ± 7.1
DR 7 282.9 ± 22.1a 1.8 ± 0.1 12.9 ± 0.7a 769.0 ± 23.2a
DR + T 6 265.8 ± 21.1a 1.8 ± 0.1 12.0 ± 1.0a 845.5 ± 46.8a
Abreviations are: CR, citrate buffer–treated control rats; DR, streptozotocin-induced diabetic rats; DR + T, streptozotocin-induced diabetic rats treated with taurine.
Data are presented as mean ± SE.
aP < 0.05 compared to citrate buffer–treated control rats.
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Fig. 7. Glomerular volume (A), fractional mesangial area (B), and urinary protein excretion (C) in study animals. Data are presented as mean
± SE. Abbreviations are: CR, control rats; DR, streptozotocin-induced diabetic rats; DR + T, streptozotocin-induced diabetic rats treated with
taurine, Numbers inside the columns are number of rats. ∗P < 0.05 compared to control rats; +P < 0.05 compared to streptozotocin-induced diabetic
rats.
glucose–induced PAI-1 secretion [abstract; Ha H, et al,
J Am Soc Nephrol 12:836A, 2001]. These observations
suggest that cellular redox potential plays an important
role in the regulation of PAI-1 expression in rat mesangial
cells cultured under serum-free media.
Anti-TGF-b antibody effectively prevented high
glucose– and H2O2-induced PAI-1 up-regulation, sug-
gesting that high glucose– and H2O2-induced PAI-1 up-
regulation is TGF-b1 dependent. Since both high glucose
and TGF-b1 induce generation of cellular ROS and ROS
mediate both high glucose– (the present data) and TGF-
b1–induced [32] PAI-1 up-regulation, it appears that ROS
amplify TGF-b1 signaling in high glucose–induced PAI-1
up-regulation.
Downstream signaling pathways involved in ROS-
induced PAI-1 mRNA expression, however, have not
been clearly defined. The promoter region of PAI-1 gene
contains several redox sensitive transcription factors such
as Sp1, activating protein-1 (AP-1), and nuclear factor-
jB (NF-jB) [7]. Hyperglycemia-induced mitochondrial
superoxide overproduction was shown to activate hex-
osamine pathway and induce PAI-1 expression in en-
dothelial cells by increasing Sp1 glycosylation [25]. In
the present study, we found that mythramycin, a Sp1
inhibitor, effectively prevented high glucose–induced
PAI-1 protein secretion by mesangial cells suggesting that
Sp1 is involved in high glucose–induced PAI-1 expression
(data not shown). Activation of protein kinase C (PKC) is
required in hexosamine-dependent PAI-1 up-regulation
in mesangial cells cultured under high glucose [22]. Vulin
and Stanley [41] demonstrated that oxidative stress ac-
tivates PAI-1 promoter through AP-1 response element
and cooperated with insulin for additive effects on PAI-1
transcription. We found that curcumin, an AP-1 inhibitor,
effectively inhibited high glucose–induced PAI-1 protein
secretion by mesangial cells (data not shown). The pre-
cise promoter regions of PAI-1 that bind transcription
factors under high glucose–induced oxidative stress re-
main a subject of future study.
The in vivo data in the present study suggest that ROS
mediate hyperglycemia-induced PAI-1 up-regulation
in streptozotocin-induced diabetic glomeruli. Taurine
significantly inhibited PAI-1 mRNA expression in
diabetic glomeruli. Up-regulation of PAI-1 mRNA in the
glomeruli of diabetic rats at 1 week after streptozotocin
agrees with a recent study [20] which demonstrated
60% to 80% increase in renal PAI-1 mRNA in dia-
betic rats at 10 days and 3 weeks after streptozotocin
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injection and 2.5-fold increase in 38-week-old Ot-
suka Long-Evans Tokushima Fatty (OLETF) rats
compared to age-matched control Long-Evans
Tokushima Otsuka (LETO) rats. PAI-1 mRNA was
observed in intraglomerular cells and tubular epithelial
cells [19]. Glomerular expression of PAI-1 protein also
increased at 4 weeks after streptozotocin, although sta-
tistically insignificant, but taurine significantly inhibited
glomerular expression of PAI-1 protein. A recent study
[20] reported increased PAI-1 protein expression at
3 weeks after streptozotocin treatment by immunohis-
tochemistry. Taurine also significantly inhibited plasma
LPO, glomerular volume, fractional mesangial area, and
urinary protein excretion in diabetic rats without effect
on plasma glucose.
It still remains unclear whether hyperglycemia-
induced PAI-1 expression and/or suppression of plasmin
is causally related to diabetic glomerulosclerosis. In this
regard, our preliminary study [abstract; Lee HB et al,
J Am Soc Nephrol 13:169A, 2002] showed that PAI-1 an-
tisense oligonucleotides, but not sense oligonucleotides,
effectively inhibited basal as well as high glucose– and
TGF-b1–induced fibronectin protein secretion. Other
studies also suggest an important role of PAI-1 in
glomerulosclerosis and tubulointerstitial fibrosis. Ad-
ministration of tPA accelerates ECM degradation in
experimental glomerulonephritis [42], crescentic nephri-
tis model of PAI-1 knockout mice exhibit reduced
renal collagen content and proteinuria compared to
wild type mice [15], unilateral ureteral obstruction in
PAI-1 knockout mice produces less tubulointerstitial fi-
brosis compared to wild type [43], and a mutant, non-
inhibitory PAI-1 decreases matrix accumulation, pro-
teinuria, and macrophage infiltration in experimental
glomerulonephritis [44].
CONCLUSION
Our present data demonstrate that ROS mediate high
glucose–induced up-regulation of PAI-1 expression in
both mesangial cells and in diabetic glomeruli. Since both
high glucose and TGF-b1 induce cellular ROS and ROS
mediate both high glucose– and TGF-b1–induced PAI-1,
ROS appear to amplify TGF-b1 signaling in high glucose–
induced PAI-1 up-regulation. Increase in PAI-1 expres-
sion may lead to diabetic glomerulosclerosis through
inhibition of ECM degradation. Antioxidants can pre-
vent accumulation of ECM protein in diabetic glomeruli
partly by abrogating up-regulation of PAI-1 and suppres-
sion of plasmin activity.
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